title: Impact of new treatment options for hepatitis C virus infection in liver transplantation.
abstract: Liver transplant candidates and recipients with hepatitis C virus (HCV)-related liver disease greatly benefit from an effective antiviral therapy. The achievement of a sustained virological response before transplantation can prevent the recurrence of post-transplant HCV disease that occurs universally and correlates with enhanced progression to graft cirrhosis. Previous standard-of-care regimens (e.g., pegylated-interferon plus ribavirin with or without first generation protease inhibitors, boceprevir and telaprevir) displayed suboptimal results and poor tolerance in liver transplant recipients. A new class of potent direct-acting antiviral agents (DAA) characterized by all-oral regimens with minimal side effects has been approved and included in the recent guidelines for the treatment of liver transplant recipients with recurrent HCV disease. Association of sofosbuvir with ribavirin and/or ledipasvir is recommended in liver transplant recipients and patients with decompensated cirrhosis. Other regimens include simeprevir, daclatasvir, and combination of other DAA. Possible interactions should be monitored, especially in coinfected human immunodeficiency virus/HCV patients receiving antiretrovirals.
authors.affiliation: Elda Righi, Angela Londero, Alessia Carnelutti, Matteo Bassetti, Infectious Diseases Division, Santa Maria della Misericordia University Hospital, 33100 Udine, Italy.
authors.forename: Elda
authors.initials: E
authors.lastname: Righi
authors.affiliation: Elda Righi, Angela Londero, Alessia Carnelutti, Matteo Bassetti, Infectious Diseases Division, Santa Maria della Misericordia University Hospital, 33100 Udine, Italy.
authors.forename: Angela
authors.initials: A
authors.lastname: Londero
authors.affiliation: Elda Righi, Angela Londero, Alessia Carnelutti, Matteo Bassetti, Infectious Diseases Division, Santa Maria della Misericordia University Hospital, 33100 Udine, Italy.
authors.forename: Alessia
authors.initials: A
authors.lastname: Carnelutti
authors.affiliation: Elda Righi, Angela Londero, Alessia Carnelutti, Matteo Bassetti, Infectious Diseases Division, Santa Maria della Misericordia University Hospital, 33100 Udine, Italy.
authors.forename: Umberto
authors.initials: U
authors.lastname: Baccarani
authors.affiliation: Elda Righi, Angela Londero, Alessia Carnelutti, Matteo Bassetti, Infectious Diseases Division, Santa Maria della Misericordia University Hospital, 33100 Udine, Italy.
authors.forename: Matteo
authors.initials: M
authors.lastname: Bassetti
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D060085:Coinfection / Q000188:drug therapy; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D008103:Liver Cirrhosis / Q000601:surgery / Q000821:virology; D016031:Liver Transplantation; D019384:Nucleic Acid Synthesis Inhibitors / Q000627:therapeutic use*; D011182:Postoperative Care; D011300:Preoperative Care; D011480:Protease Inhibitors / Q000627:therapeutic use; D012367:RNA, Viral / Q000096:biosynthesis*; D012008:Recurrence
chemical_list: D000998:Antiviral Agents; D019384:Nucleic Acid Synthesis Inhibitors; D011480:Protease Inhibitors; D012367:RNA, Viral
keywords: Direct antiviral agents; Hepatitis C virus; Liver transplantation